Management of Tirzepatide-Associated Diarrhea

Initial Clinical Assessment

• The American Society of Clinical Oncology recommends evaluating stool characteristics, including frequency, consistency, presence of blood, and nocturnal occurrence, to determine severity and guide management 1
• The Centers for Disease Control and Prevention suggests assessing hydration status by checking for tachycardia, orthostatic hypotension, decreased skin turgor, dry mucous membranes, altered mental status, and decreased urine output 2

Risk Stratification and Severity Grading

• The Journal of Clinical Oncology defines mild diarrhea as increased frequency but maintaining hydration, no systemic symptoms, and recommends outpatient management 1
• The MMWR Recommendations and Reports defines moderate diarrhea as frequent loose stools with early dehydration signs and requires close monitoring 2
• The Journal of Clinical Oncology defines severe diarrhea as profuse watery stools with dehydration, fever, or systemic symptoms, and recommends considering hospitalization and aggressive intervention 1

Immediate Management Steps

Hydration Management

• The MMWR Recommendations and Reports recommends administering oral rehydration solution (ORS) 50 mL/kg over 2-4 hours for mild dehydration 2
• The Journal of Clinical Oncology suggests instructing patients to drink 8-10 large glasses of clear liquids daily for mild dehydration 1
• The MMWR Recommendations and Reports recommends initiating intravenous fluid resuscitation with normal saline or Ringer's lactate for moderate to severe dehydration 2

Dietary Modifications

• The Journal of Clinical Oncology recommends eliminating all lactose-containing products, alcohol, and high-osmolar dietary supplements immediately regardless of severity 1
• The Journal of Clinical Oncology suggests recommending a BRAT diet (bananas, rice, applesauce, toast, plain pasta) immediately regardless of severity 1
• The Journal of Clinical Oncology recommends eating frequent small meals rather than large portions 1

Symptomatic Treatment

• The Journal of Clinical Oncology recommends an initial dose of 4 mg of loperamide, then 2 mg every 4 hours or after each unformed stool (maximum 16 mg/day) for persistent diarrhea after dietary modifications 1
• The Praxis Medical Insights recommends not using loperamide if the patient has fever, bloody stools, or suspected infectious etiology 3

Critical Monitoring Parameters

• The Journal of Clinical Oncology recommends instructing patients to track and report the number and consistency of stools daily 1
• The MMWR Recommendations and Reports suggests instructing patients to report symptoms of severe dehydration, such as dizziness upon standing, decreased urination, and confusion 2
• The Journal of Clinical Oncology recommends instructing patients to report fever (>100.4°F/38°C) suggesting infectious complications 1

Special Considerations and Pitfalls

• The Praxis Medical Insights recommends obtaining stool studies for bacterial pathogens and C. difficile before initiating antimotility agents if fever, bloody stools, or recent antibiotic use are present 3

When to Escalate Care

• The Praxis Medical Insights recommends hospitalization for severe dehydration despite oral rehydration attempts, hemodynamic instability, inability to tolerate oral fluids, and signs of acute kidney injury 3